These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 20522797)

  • 21. The role of selective estrogen receptor modulators on breast cancer: from tamoxifen to raloxifene.
    Lee WL; Cheng MH; Chao HT; Wang PH
    Taiwan J Obstet Gynecol; 2008 Mar; 47(1):24-31. PubMed ID: 18400579
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effect of raloxifene on the incidence of invasive breast cancer in postmenopausal women with osteoporosis categorized by breast cancer risk.
    Lippman ME; Cummings SR; Disch DP; Mershon JL; Dowsett SA; Cauley JA; Martino S
    Clin Cancer Res; 2006 Sep; 12(17):5242-7. PubMed ID: 16951244
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Raloxifene works as well as tamoxifen in preventing invasive breast cancer.
    Mayo Clin Womens Healthsource; 2006 Oct; 10(10):3. PubMed ID: 16977270
    [No Abstract]   [Full Text] [Related]  

  • 24. Risks, benefits, and effects on quality of life of selective estrogen-receptor modulator therapy in postmenopausal women at increased risk of breast cancer.
    Ganz PA; Land SR
    Menopause; 2008; 15(4 Suppl):797-803. PubMed ID: 18596601
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Chemoprevention of breast cancer: recommendations and rationale.
    Berg AO;
    Am J Nurs; 2003 May; 103(5):107, 109, 111, 113. PubMed ID: 12759615
    [No Abstract]   [Full Text] [Related]  

  • 26. Drugs can reduce the incidence of breast cancer: now what?
    Wozniak TF; Eppes PG; Wilson CT
    Del Med J; 1999 Sep; 71(9):387-9. PubMed ID: 10584440
    [No Abstract]   [Full Text] [Related]  

  • 27. [Which is the better choice, estrogen or SERMs in postmenopausal women?].
    Shintani M
    Clin Calcium; 2004 Oct; 14(10):105-10. PubMed ID: 15577140
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Selective estrogen receptor modulators (SERMs) in the practice].
    Nagykálnai T
    Magy Onkol; 2002; 46(2):165-75. PubMed ID: 12202896
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Selective estrogen-receptor modulators (SERM's) in postmenopausal women].
    Hart W; Netelenbos JC
    Ned Tijdschr Geneeskd; 1999 Aug; 143(35):1771-6. PubMed ID: 10494328
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Selective estrogen-receptor modulators in 2001.
    O'Regan RM; Gradishar WJ
    Oncology (Williston Park); 2001 Sep; 15(9):1177-85, 1189-90; discussion 1190-4. PubMed ID: 11589065
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Breast cancer risk reduction: what do we know and where should we go?
    Prout MN
    Medscape Womens Health; 2000; 5(5):E4. PubMed ID: 11113777
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Chemoprevention of breast cancer. Clinical trials in pharmacological prevention].
    Ricart JJ
    Medicina (B Aires); 2004; 64(1):66-72. PubMed ID: 15034961
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Carcinoma in situ outcomes in National Surgical Adjuvant Breast and Bowel Project Breast Cancer Chemoprevention Trials.
    Vogel VG; Costantino JP; Wickerham DL; McCaskill-Stevens W; Clarfeld RB; Grant MD; Wolmark N
    J Natl Cancer Inst Monogr; 2010; 2010(41):181-6. PubMed ID: 20956826
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The STAR (Study of Tamoxifen and Raloxifene) trial in West Virginia.
    Jubelirer SJ; Crowell EB
    W V Med J; 2000; 96(6):602-4. PubMed ID: 11194089
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Selective estrogen-receptor modulators for primary prevention of breast cancer.
    Fabian CJ; Kimler BF
    J Clin Oncol; 2005 Mar; 23(8):1644-55. PubMed ID: 15755972
    [No Abstract]   [Full Text] [Related]  

  • 36. National surgical adjuvant breast and bowel project update: prevention trials and endocrine therapy of ductal carcinoma in situ.
    Vogel VG; Costantino JP; Wickerham DL; Cronin WM
    Clin Cancer Res; 2003 Jan; 9(1 Pt 2):495S-501S. PubMed ID: 12538506
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Relationship between bone mass, invasive breast cancer incidence and raloxifene therapy in postmenopausal women with low bone mass or osteoporosis.
    Burshell AL; Song J; Dowsett SA; Mershon JL; Delmas PD; Secrest RJ; Cauley JA
    Curr Med Res Opin; 2008 Mar; 24(3):807-13. PubMed ID: 18254988
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Raloxifene: a selective modulator of estrogen receptors].
    van den Brûle FA; Kalbus MF; Gaspard UJ
    J Gynecol Obstet Biol Reprod (Paris); 1999 Dec; 28(8):788-99. PubMed ID: 10635481
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Antiestrogens and selective estrogen receptor modulators as multifunctional medicines. 2. Clinical considerations and new agents.
    Jordan VC
    J Med Chem; 2003 Mar; 46(7):1081-111. PubMed ID: 12646017
    [No Abstract]   [Full Text] [Related]  

  • 40. Prevention of breast cancer using selective oestrogen receptor modulators (SERMs).
    Powles TJ
    Breast Cancer Res; 2006; 8(5):111. PubMed ID: 17049068
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.